InvestmentApr 30, 2026, 03:02 PM
ABBV Awards Biotechnology Innovators Prize to RIME Therapeutics
AI Summary
AbbVie Inc., in collaboration with adMare BioInnovations, has awarded the AbbVie Biotechnology Innovators Award to RIME Therapeutics, a Montreal-based startup. This award aims to foster innovation and growth in Quebec's life sciences sector. RIME Therapeutics, founded in 2025, is developing a peptide-based drug discovery platform targeting protein-protein interactions for inflammation and immune disorders. The prize includes one year of free lab and office space, shared services at adMare Innovation Centre, and mentorship from AbbVie's commercial and scientific leaders, supporting RIME's research in areas aligned with AbbVie's therapeutic focus.
Key Highlights
- AbbVie and adMare BioInnovations awarded the Biotechnology Innovators Award to RIME Therapeutics.
- RIME Therapeutics is a Montreal startup developing a peptide-based drug discovery platform.
- The platform targets protein-protein interactions for inflammation and immune disorders.
- RIME receives one year of free lab and office space at adMare Innovation Centre in Montreal.
- RIME will also benefit from shared equipment, services, and mentorship from AbbVie leaders.
- The award aims to foster innovation in Quebec's life sciences ecosystem.
Price Impact
More from ABBV